Belite Bio Incorporation

BLTE

Equity

ISIN null / Valor 118450378

NASDAQ (2026-04-01)

USD 167.25+4.90%

Belite Bio Incorporation
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Belite Bio Inc. is a biopharmaceutical company focused on developing innovative therapies for conditions with significant unmet medical needs, particularly in the areas of ophthalmology, liver disease, and diabetes. The company's lead candidate, Tinlarebant, is an oral therapy designed to address the accumulation of toxins in the eye associated with Stargardt disease (STGD1) and geographic atrophy (GA). Tinlarebant has progressed through a two-year Phase 2 study in adolescent STGD1 patients and is currently undergoing further evaluation in Phase 3 and Phase 2/3 studies, including the DRAGON and PHOENIX trials. The drug has received Orphan Drug Designation in the United States, Europe, and Japan, as well as additional designations such as Rare Pediatric Disease and Fast Track in the US, and Sakigake in Japan. Belite Bio's research and development efforts are anchored in its proprietary Retinol Binding Protein 4 (RBP4) intellectual property portfolio, which underpins its pipeline of novel therapies aimed at treating blindness and other serious health conditions.

Summarized from source with an LLMView SourceSector: Finance

Latest Results ():

Summarized from source with an LLMView Source

Key figures

157%1Y

476%3Y

%5Y

Performance

51.6%1Y

62.3%3Y

73.2%5Y

Volatility